Back to top

The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger

Read MoreHide Full Article

For Immediate Release

Chicago, IL – September 12, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Gilead (Nasdaq:(GILD - Free Report)  Free Report), Oracle (NYSE:(ORCL - Free Report)  Free Report), Morgan Stanley (NYSE:(MS - Free Report)  Free Report), Expedia (Nasdaq:(EXPE - Free Report)  Free Report) and Kroger (NYSE:(KR - Free Report) Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday’s Analyst Blog:

Top Stocks Reports for Gilead, Oracle, Morgan Stanley and More

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Gilead (Nasdaq:(GILD - Free Report) Free Report), Oracle (NYSE:(ORCL - Free Report) Free Report) and Morgan Stanley (NYSE:(MS - Free Report) Free Report). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Gilead’s shares have outperformed the Zacks Biotech industry year to date, gaining +20.7% vs. +17.1%. Gilead is all set to acquire Kite Pharma and enter the CAR T therapy space which represents immense potential at this juncture and a potential approval of lead candidate axi-cell will be a significant boost for Gilead’s prospects which have dampened of late.

The Zacks analyst emphasizes that an acquisition announcement was on the cards as Gilead had a strong cash balance and the decline in the once lucrative hepatitis C (HCV) market due to competitive pressure made the company look for strategic alternatives. Gilead is known for its presence in the HCV market because of its blockbuster HCV drugs, Sovaldi and Harvoni.

However, the HCV franchise is under pressure because of competition and pricing issues. Meanwhile, the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens in the U.S. and EU.

(You canread the full research report on Gilead here >>>).

Shares of Oracle have outperformed the Zacks Technology Sector year-to-date, gaining +35.7% vs. +19%. Oracle is benefiting from significant momentum in the SaaS and PaaS offerings. The Zacks analyst thinks the company’s growing cloud market share will continue to drive top-line growth for the foreseeable future.

The recent collaboration with Mitsubishi and addition of AI and machine learning features in  Internet of Things (IoT) Cloud offerings is encouraging. NetSuite continues to expand customer base and was recently named as a leader among B2B commerce suites for midsize organizations by Forrester Wave report.

Meanwhile, estimates have been stable lately ahead of the company's Q1 earnings release. The company has mixed record of earnings surprises in recent quarters. However, higher investments on IaaS will affect gross margin expansion in the near-term.

(You can read the full research report on Oracle here >>>).

Buy-rated Morgan Stanley’s shares have outperformed the Zacks Finance sector over the last one year, gaining +39.3% versus the sector’s +18.9% increase. The performance was supported by the company’s impressive earnings surprise history. Earnings have surpassed expectations in each of the trailing four quarters.

The Zacks analyst likes the company’s efforts to offload its non-core assets to lower balance sheet risk and cost saving initiatives (Project Streamline), which will likely lead to improvement in profitability. These initiatives, along with enhanced capital deployment should boost investors’ confidence in the stock. 

However, continued fall in corporate loan balances leading to decline in interest income remains a near-term concern for the company. (You can read the full research report on Morgan Stanley here >>>).

Other noteworthy reports we are featuring today include Expedia (Nasdaq:(EXPE - Free Report) Free Report) and Kroger (NYSE:(KR - Free Report) Free Report).

4 Surprising Tech Stocks to Keep an Eye On

Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.

See Stocks Now>>

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Get the full Report on GILD - FREE

Get the full Report on ORCL - FREE

Get the full Report on MS - FREE

Get the full Report on EXPE - FREE

Get the full Report on KR - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.



More from Zacks Press Releases

You May Like